Sua seleção (0)
Detalhe da pesquisa
1.
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood;
132(4): 393-404, 2018 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567798
2.
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Haematologica;
102(2): 327-335, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27789678
3.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
N Engl J Med;
366(9): 799-807, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22375971
4.
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Blood;
120(25): 4945-51, 2012 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-22915641
5.
A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.
Haematologica;
99(7): 1176-83, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24488560
6.
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
Haematologica;
99(2): 292-8, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23911705
7.
Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome.
J Immunol;
189(6): 3198-208, 2012 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22875800
8.
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Br J Haematol;
161(4): 508-16, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23480528
9.
Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia.
Blood;
118(16): 4384-93, 2011 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21865345
10.
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.
Blood;
117(17): 4552-60, 2011 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-21285439
11.
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.
Blood;
117(21): e198-206, 2011 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21346257
12.
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Haematologica;
98(12): 1865-71, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24038026
13.
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
Blood;
115(5): 1049-53, 2010 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965645
14.
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
J Clin Invest;
117(9): 2562-9, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17710227
15.
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Cancer Cell;
2(2): 117-25, 2002 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12204532
16.
Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.
Br J Haematol;
142(3): 379-93, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18540943
17.
Systemic mastocytosis with plasma cell dyscrasia: report of a case.
Leuk Res;
32(7): 1160-3, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18061667
18.
Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia.
Leuk Res;
32(5): 823-7, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17915315
19.
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
J Hematol Oncol;
10(1): 156, 2017 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28962635
20.
Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.
Oncotarget;
8(38): 64651, 2017 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28969101